Summary of minutes of EUCAST Steering Committee Meeting
Stockholm, Sweden 7-8 July 2014

Attending
Dr Derek F.J. Brown DB  Scientific Secretary  United Kingdom
Dr Rafael Cantón RC  Chairperson  Spain
Prof Gerard Lina GL  CA-SFM  France
Dr Christian Giske CG  SRGA  Sweden
Prof Gunnar Kahlmeter GK  Clinical Data Co-ordinator  Sweden
Dr Robin Howe RH  BSAC  United Kingdom
Dr Iztok Štrumbelj IS  EUCAST General Committee  Slovenia
Prof Johan W. Mouton JM  CRG  The Netherlands
Prof Sören Gatermann SG  EUCAST General Committee  Germany
Dr Martin Steinbakk MS  NWGA  Norway
Prof Jan Verhagen JV  EUCAST General Committee  Belgium

Apologies
Prof Luc Dubreuil LD  CA-SFM  France
Prof Alasdair P. MacGowan AM  BSAC  United Kingdom

Visiting members:
Prof Ron Jones RJ  EUCAST General Committee  USA
Dr Radu Botgros RB  EMA  UK

Present for items 4, 16, 20-22
Magnus Unemo MU  Örebro University Hospital  Sweden
Gianfranco Spiteri ECDC  Sweden

Present for item 7 (N. gonorrhoeae)

Present for item 17

Present for item 21

Company representatives

1  Chairman’s welcome

2  Minutes of meeting of 13-14 May 2014 With minor modifications the minutes were accepted as a correct record.

3  Matters arising from minutes of 13-14 May 2014 (items not covered by agenda) Approaches to incorporation of expert rules in breakpoint tables is being reviewed.

4  New agents
Bedaquiline: At present only the breakpoints will be listed on the website. QC data for the broth microdilution method will be added when reproducibility data are available.

New glycopeptide: Breakpoint discussions are continuing.

5  EUCAST rationale documents
The revised rationale document template is on the website and old rationale documents will be updated over a period of time.

Ceftaroline and ceftobiprole documents are close to completion and outstanding documents on macrolides, aztreonam, penicillins and trimethoprim-sulfamethoxazole will be reviewed again and released as soon as possible.

6  Subcommittees Antifungal susceptibility testing subcommittee documents on MIC determination for moulds, and itraconazole breakpoints for Candida spp. will be released on the EUCAST website.

7  Breakpoint issues
A note about the revised telavancin MIC method and breakpoints will be released as an addendum to breakpoint tables.
For *Neisseria meningitidis* a proposal for ciprofloxacin breakpoints of S ≤ 0.03, R > 0.03 mg/L, without an intermediate category, will be released for consultation.

Breakpoints and susceptibility testing methods for *Neisseria gonorrhoeae* and proposals for further work were discussed.

For *Acinetobacter* spp., proposals for sulbactam breakpoints are being prepared, use of cefoperazone-sulbactam is being assessed and comment on usage of combinations including rifampicin is being considered.

Possible modifications to carbapenem breakpoints are being considered.

A document on organism-agent combinations lacking clinical data to support breakpoints has been released on the website.

A document on reporting of dissociated resistance to clindamycin will be released for consultation.

Proposed changes to expert rules are being reviewed.

A meeting to produce guidelines for manufacturers on data required for new antimycobacterial agents is being organised.

The implications for oral and iv treatment of infections caused by ampicillin-amoxicillin intermediate *Streptococcus pneumoniae* are being assessed.

The requirements for daptomycin breakpoints for enterococci from endocarditis and bacteraemia, for nitroxoline breakpoints for *E. coli* in UTI, and for temocillin breakpoints for Enterobacteriaceae are being assessed.

The need for review of tigecycline breakpoints for Enterobacteriaceae is being assessed.

Ciprofloxacin and moxifloxacin MICs for *Corynebacterium* spp have been correlated and will be added to the website calibration file on *Corynebacterium* spp.

Teicoplanin ECOFFs for coagulase-negative staphylococci are being reviewed.

A “Question and Answer” on fosfomycin breakpoints and susceptibility testing is being prepared.

<table>
<thead>
<tr>
<th>8</th>
<th>Organisms without EUCAST breakpoints</th>
<th>Work on methods for <em>Actinomyces</em> spp. Is continuing.</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>EUCAST methods</td>
<td>A broth microdilution MIC determination service will soon be announced on the EUCAST website.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Use of vancomycin susceptibility as surrogate for lipoglycopeptide susceptibility is being assessed.</td>
</tr>
<tr>
<td>10</td>
<td>Implementation of EUCAST breakpoints</td>
<td>No new information.</td>
</tr>
<tr>
<td>11</td>
<td>EUCAST websites</td>
<td>An antimycobacterial agents section is being developed.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>There is considerable interest in development of an international MIC distribution website based on the EUCAST MIC distribution website.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Summary website statistics show extensive use of the EUCAST website.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Documents describing EUCAST Network and Development Laboratories are being prepared.</td>
</tr>
<tr>
<td>12</td>
<td>Publications and presentations</td>
<td>A paper on uptake of EUCAST breakpoints is being assessed by Euro Surveillance.</td>
</tr>
<tr>
<td>13</td>
<td>NACs</td>
<td>A report on multiple activities of USCAST (USA NAC) was received.</td>
</tr>
</tbody>
</table>
**EUCAST SOPs**
SOP 8.0 on update and format of EUCAST documents is released on the EUCAST website.

SOP 4.0 on EUCAST committees has been revised and version 4.1 will be released on the website.

SOP 9.0 on Development of QC criteria and zone diameter breakpoints is being developed.

**ESCMID**
EUCAST proposals for sessions at ECCMID 2015 have been submitted.

The programme is complete and applications are being received for the Postgraduate Educational Course, Linz, Tuesday 16th – Friday 19th September 2014.

**EMA**
The EMA-EUCAST SOP is now being revised.

The position of EMA regarding changes to breakpoints previously set according to the EMA-EUCAST SOP is to be clarified.

**ECDC**
There was discussion of ECDC issues including the next contract, susceptibility testing of isolates from food animals, relationships between EUCAST and countries outside Europe, and mapping of EUCAST uptake.

**CLSI**
A verbal report on the June 2014 meeting was received.

**Recommendations on generation and reporting of statistics on bacterial resistance**
ESCMID study groups will be asked if they are working on this topic.

**New oxazolidinone agent**
The agent was presented by the company and breakpoints discussed.

**Any other business**
None.

**Next meetings**
15-16 September 2014, Linz, Austria.
10-11 November 2014, Basel, Switzerland.
16-17 February 2015, Brussels, Belgium.
28-29 April 2015, Copenhagen, Denmark

Ratified summary of minutes of meeting 7-8 July 2014. Prepared by DB, RC and GK